Suggested remit: To appraise the clinical and cost effectiveness of maralixibat within its marketing authorisation for treating progressive familial intrahepatic cholestasis.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 3818

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
29 September 2023 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
07 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
22 August 2023 The topic routing was considered by the Topic Selection Oversight Panel (TSOP) in July 2023. The panel concluded that the topic should be routed to the Technology Appraisal (TA) work programme. Please see project documents for further details
22 August 2023 Topic selection
20 March 2023 - 19 April 2023 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 3818
20 March 2023 In progress
21 December 2022 Discontinued
29 October 2021 Suspended
01 March 2021 (14:00) Scoping workshop
08 January 2021 - 05 February 2021 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
08 January 2021 Draft scope documents

For further information on our processes and methods, please see our CHTE processes and methods manual